As the core regulatory and technical framework in drug development, Chemistry, Manufacturing, and Controls (CMC) supports regulatory approval, safety and commercial scalability. It accounts for the active pharmaceutical ingredient (API), drug formulation, and manufacturing controls required for global regulatory filings. CMC also validates that small-batch lab processes can be safely scaled to commercial manufacturing without altering the drug’s properties.

In today’s drug development landscape, minimizing the time between molecule batch and finished drug product, AI-assisted development support, phase-appropriate and small-batch supply strategies, and greater demand for expert guidance across development are among the key trends in CMC.

Experienced CDMOs and CROs can help identify technical and regulatory risks early, evaluate alternative development pathways, and support decisions that improve development efficiency, reduce downstream risk, and help sponsors reach critical milestones with greater confidence.

Kevin Kane, PhD, CMC Strategy Director, PPD Strategic Scientific Solutions (S3), Thermo Fisher Scientific, shares insight on the dynamics reshaping expectations for CMC strategy and execution.

Contract Pharma: What industry trends are having the most impact on the CMC landscape?

Kevin Kane: Sponsors today are operating in an environment defined by increasing molecule complexity, tighter funding conditions, and pressure to reach value inflection points more quickly. These dynamics are…